Monoamine Oxidase-B Inhibition in Alzheimer's Disease

NeuroToxicology

Volumn 25, Issue 1-2, 2004, Pages 271-277

  Riederer, Peter ^a   Danielczyk, Walter ^b   Grünblatt, Edna ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

Author keywords

Alzheimer's disease; Deprenyl; Lazabemide; Monoamine oxidase B; Rasagiline

Indexed keywords

AMYLOID BETA PROTEIN; ANTIDEPRESSANT AGENT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; APOLIPOPROTEIN E4; CARBAMIC ACID DERIVATIVE; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; CLORGYLINE; ESTROGEN; IBUPROFEN; IPRONIAZID; ISOCARBOXAZID; LADOSTIGIL; LAZABEMIDE; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE B INHIBITOR; N PROPARGYLAMINOINDAN 5 YLETHYLMETHYLCARBAMATE; NIALAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENELZINE; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN INHIBITOR; RASAGILINE; RIVASTIGMINE; SELEGILINE; TRACE ELEMENT; TRANYLCYPROMINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; DRUG POTENCY; DRUG SAFETY; DRUG TOLERANCE; HUMAN; LIFESPAN; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

GYMNOMYZA SAMOENSIS;

EID: 0348046385     PISSN: 0161813X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-813X(03)00106-2     Document Type: Article

References (93)

1. Adolfsson R, Gottfries CG, Oreland L, Wiberg A, Winblad B. Increased activity of brain and platelet monoamine oxidase in dementia of Alzheimer type. Life Sci 1980;27:1029-34.
2. Alexopoulos GS, Young RC, Lieberman KW, Shamoian CA. Platelet MAO activity in geriatric patients with depression and dementia. Am J Psychiatr 1987;144:1480-3.
3. Bliss TV, Collingridge GL. A synaptic model of memory: long-term potentiation in the hippocampus. Nature 1993;361:31-9.
4. Bonuccelli U, Piccini P, Marazziti D, Cassano GB, Muratorio A. Increased platelet 3H-imipramine binding and monoamine oxidase B activity in Alzheimer's disease. J Neural Transm Park Dis Dement Sect 1990;2:139-47.
5. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998;88:1337-42.
6. Carrillo MC, Kanai S, Nokubo M, Kitani K. (-)Deprenyl induces activities of both superoxide dismutase and catalase but not of glutathione peroxidase in the striatum of young male rats. Life Sci 1991;48:517-21.
7. Carrillo MC, Minami C, Kitani K, Maruyama W, Ohashi K, Yamamoto T et al. Enhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system in the rat. Life Sci 2000;67:577-85.
8. Cesura AM, Borroni E, Gottowik J, Kuhn C, Malherbe P, Martin J et al. Lazabemide for the treatment of Alzheimer's disease: rationale and therapeutic perspectives. Adv Neurol 1999;80:521-8.
9. Chakravorty SG, Halbreich U. The influence of estrogen on monoamine oxidase activity. Psychopharmacol Bull 1997;33:229-33.
10. Christen Y. Oxidative stress and Alzheimer disease. Am J Clin Nutr 2000;71:621S-9S.
11. Ciccone CD. Free-radical toxicity and antioxidant medications in Parkinson's disease. Phys Ther 1998;78:313-9.
12. Cohen G, Spina MB. Deprenyl suppresses the oxidant stress associated with increased dopamine turnover. Ann Neurol 1989;26:689-90.
13. Cooper A. Glutathione in the brain: disorders of glutathione metabolism. In: Rosenberg R, Prusiner S, DiMauro S, Barchi R, Klunk L (Eds.), The molecular and genetic basis of neurological disease. Boston: Butterworth-Heinemann.
14. Cruts M, van Broeckhoven C. Molecular genetics of Alzheimer's disease. Ann Med 1998;30:560-5.
15. Cutler NR, Sramek JJ. Review of the next generation of Alzheimer's disease therapeutics: challenges for drug development. Prog Neuropsychopharmacol Biol Psychiatr 2001;25:27-57.
16. Danielczyk W, Streifler M, Konradi C, Riederer P, Moll G. Platelet MAO-B activity and the psychopathology of Parkinson's disease. Acta Psychiatr Scand 1988;78:730-6.
17. Doraiswamy PM. Non-cholinergic strategies for treating and preventing Alzheimer's disease. CNS Drugs 2002;16:811-24.
18. Du Y, Dodel RC, Eastwood BJ, Bales KR, Gao F, Lohmuller F et al. Association of an interleukin 1 alpha polymorphism with Alzheimer's disease. Neurology 2000;55:480-3.
19. Eliash S, Speiser Z, Cohen S. Rasagiline and its (S) enantiomer increase survival and prevent stroke in salt-loaded stroke-prone spontaneously hypertensive rats. J Neural Transm 2001;108:909-23.
20. Finali G, Piccirilli M, Oliani C, Piccinin GL. L-Deprenyl therapy improves verbal memory in amnesic Alzheimer patients. Clin Neuropharmacol 1991;14:523-36.
21. Finberg JP, Takeshima T, Johnston JM, Commissiong JW. Increased survival of dopaminergic neurons by rasagiline: a monoamine oxidase B inhibitor. Neuroreport 1998;9:703-7.
22. Finberg JP, Lamensdorf I, Weinstock M, Schwartz M, Youdim MB. Pharmacology of rasagiline (N-propargyl-1R-aminoindan). Adv Neurol 1999;80:495-9.
23. Fischer P, Gotz ME, Ellinger B, Streifler M, Riederer P, Danielczyk W. Platelet monoamine oxidase B activity and Vitamin B12 in dementia. Biol Psychiatry 1994;35:772-4.
24. Fowler CJ, Wiberg A, Oreland L, Marcusson J, Winblad B. The effect of age on the activity and molecular properties of human brain monoamine oxidase. J Neural Transm 1980;49:1-20.
25. Gerlach M, Youdim MB, Riederer P. Pharmacology of selegiline. Neurology 1996;47:S137-45.
26. Glover V, Gibb C, Sandler M. The role of MAO in MPTP toxicity: a review. J Neural Transm Suppl 1986;20:65-76.
27. Goggi J, Theofilopoulos S, Riaz SS, Jauniaux E, Stern GM, Bradford HF. The neuronal survival effects of rasagiline and deprenyl on fetal human and rat ventral mesencephalic neurones in culture. Neuroreport 2000;11:3937-41.
28. Gottfries CG, Adolfsson R, Aquilonius SM, Carlsson A, Eckernas SA, Nordberg A et al. Biochemical changes in dementia disorders of Alzheimer type (AD/SDAT). Neurobiol Aging 1983;4:261-71.
29. Gotz ME, Kunig G, Riederer P, Youdim MB. Oxidative stress: free radical production in neural degeneration. Pharmacol Ther 1994;63:37-122.
30. Gotz ME, Fischer P, Gsell W, Riederer P, Streifler M, Simanyi M et al. Platelet monoamine oxidase B activity in dementia: a 4-year follow-up. Dement Geriatr Cogn Disord 1998;9:74-7.
31. Greenawalt JW, Schnaitman C. An appraisal of the use of monoamine oxidase as an enzyme marker for the outer membrane of rat liver mitochondria. J Cell Biol 1970;46:173-9.
32. Halliwell B, Gutteridge J. Free Radicals in Biology and Medicine. Oxford: Oxford University Press.
33. Hazel JR, Williams EE. The role of alterations in membrane lipid composition in enabling physiological adaptation of organisms to their physical environment. Prog Lipid Res 1990;29:167-227.
34. Huang W, Chen Y, Shohami E, Weinstock M. Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse. Eur J Pharmacol 1999;366:127-35.
35. Johnston JP. Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 1968;17:1285-97.
36. Jossan SS, Gillberg PG, Gottfries CG, Karlsson I, Oreland L. Monoamine oxidase B in brains from patients with Alzheimer's disease: a biochemical and autoradiographical study. Neuroscience 1991;45:1-12.
37. Kesslak JP. Can estrogen play a significant role in the prevention of Alzheimer's disease? J. Neural. Transm. Suppl 2002;227-39.
38. Klegeris A, McGeer PL. R-(-)-Deprenyl inhibits monocytic THP-1 cell neurotoxicity independently of monoamine oxidase inhibition. Exp Neurol 2000;166:458-64.
39. Knoll J. The striatal dopamine dependency of life span in male rats: longevity study with (-)deprenyl. Mech Ageing Dev 1988;46:237-62.
40. Lai CT, Zuo DM, Yu PH. Is brain superoxide dismutase activity increased following chronic treatment with 1-deprenyl? J Neural Transm Suppl 1994;41:221-9.
41. Langston JW. Selegiline as neuroprotective therapy in Parkinson's disease: concepts and controversies. Neurology 1990;40(Suppl): 61-6 [discussion 67-9].
42. Luedecking EK, DeKosky ST, Mehdi H, Ganguli M, Kamboh MI. Analysis of genetic polymorphisms in the transforming growth factor-beta1 gene and the risk of Alzheimer's disease. Hum Genet 2000;106:565-9.
43. Magyar K. Behaviour of (-)-deprenyl and its analogues. J Neural Transm Suppl 1994;41:167-75.
44. Magyar K, Vizi ES, Ecseri Z, Knoll J. Comparative pharmacological analysis of the optical isomers of phenyl-isopropylmethyl-propinylamine (E-250). Acta Physiol Acad Sci Hung 1967;32:377-87.
45. Mangoni A, Grassi MP, Frattola L, Piolti R, Bassi S, Motta A et al. Effects of a MAO-B inhibitor in the treatment of Alzheimer disease. Eur Neurol 1991;31:100-7.
46. Maruyama W, Akao Y, Youdim MB, Naoi M. Neurotoxins induce apoptosis in dopamine neurons: protection by N-propargylamine-1(R)- and (S)-aminoindan, rasagiline and TV1022. J Neural Transm Suppl 2000a;171-86.
47. Maruyama W, Yamamoto T, Kitani K, Carrillo MC, Youdim M, Naoi M. Mechanism underlying anti-apoptotic activity of a (-)deprenyl-related propargylamine, rasagiline. Mech Ageing Dev 2000;116:181-91.
48. Marx J. Searching for drugs that combat Alzheimer's. Science 1996;273:50-3.
49. Mason RP, Olmstead EG, Jacob RF. Antioxidant activity of the monoamine oxidase B inhibitor lazabemide. Biochem Pharmacol 2000;60:709-16.
50. McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 1996;47:425-32.
51. Meng G, Yuan J, An L, Gong J, Zhu H, Cui S et al. An association study of polymorphisms in the alpha-antichymotrypsin gene for Alzheimer disease in Han-Chinese. Hum Mutat 2000;16:275-6.
52. Nakamura S, Kawamata T, Akiguchi I, Kameyama M, Nakamura N, Kimura H. Expression of monoamine oxidase B activity in astrocytes of senile plaques. Acta Neuropathol Berl 1990;80:419-25.
53. Nicoll JA, Mrak RE, Graham DI, Stewart J, Wilcock G, MacGowan S et al. Association of interleukin-1 gene polymorphisms with Alzheimer's disease. Ann Neurol 2000;47:365-8.
54. Oreland L, Gottfries CG. Brain and brain monoamine oxidase in aging and in dementia of Alzheimer's type. Prog Neuropsychopharmacol Biol Psychiatr 1986;10:533-40.
55. Parkinson Study Group. A controlled trial of lazabemide (RO19-6327) in untreated Parkinson's disease: Parkinson Study Group. Ann Neurol 1993;33:350-6.
56. Parkinson Study Group. A controlled trial of lazabemide (Ro 19-6327) in levodopa-treated Parkinson's disease: Parkinson Study Group. Arch Neurol 1994;51:342-7.
57. Parkinson Study Group. Effect of lazabemide on the progression of disability in early Parkinson's disease: The Parkinson Study Group. Ann Neurol 1996;40:99-107.
58. Parnetti L, Mecocci P, Reboldi GP, Santucci C, Brunetti M, Gaiti A et al. Platelet MAO-B activity and Vitamin B12 in old age dementias. Mol Chem Neuropathol 1992;16:23-32.
59. Parnetti L, Reboldi GP, Santucci C, Santucci A, Gaiti A, Brunetti M et al. Platelet MAO-B activity as a marker of behavioural characteristics in dementia disorders. Aging Milano 1994;6:201-7.
60. Pasinetti GM. From epidemiology to therapeutic trials with anti-inflammatory drugs in Alzheimer's disease: the role of NSAIDs and cyclooxygenase in beta-amyloidosis and clinical dementia. J Alzheimers Dis 2002;4:435-45.
61. Piccinin GL, Finali G, Piccirilli M. Neuropsychological effects of L-deprenyl in Alzheimer's type dementia. Clin Neuropharmacol 1990;13:147-63.
62. Prasad KN, Cole WC, Prasad KC. Risk factors for Alzheimer's disease: role of multiple antioxidants, non-steroidal anti-inflammatory and cholinergic agents alone or in combination in prevention and treatment. J Am Coll Nutr 2002;21:506-22.
63. Ptok U, Barkow K, Heun R. Fertility and number of children in patients with Alzheimer's disease. Arch Women Ment Health 2002;5:83-6.
64. Reinikainen KJ, Paljarvi L, Halonen T, Malminen O, Kosma VM, Laakso M et al. Dopaminergic system and monoamine oxidase-B activity in Alzheimer's disease. Neurobiol Aging 1988;9:245-52.
65. Riederer P, Jellinger K. Morphological and biochemical changes in the aging brain: pathophysiological and possible therapeutic consequences. Exp Brain Res 1982;Suppl: 158-66.
66. Riederer P, Youdim M. The therapeutic place and value of present and future MAO-B inhibitors L-deprenyl as the gold standard. In: Szelenyi J (Ed.), Inhibition of monoamine oxidase b, pharmacology and clinical use in neurodegenerative disorders. Basel: Birkhäuser.
67. Riederer P, Youdim MB, Rausch WD, Birkmayer W, Jellinger K, Seemann D. On the mode of action of L-deprenyl in the human central nervous system. J Neural Transm 1978;43:217-26.
68. Riederer P, Sofic E, Rausch WD, Schmidt B, Reynolds GP, Jellinger K et al. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 1989;52:515-20.
69. Sano M, Ernesto C, Klauber MR, Schafer K, Woodbury P, Thomas R et al. Rationale and design of a multicenter study of selegiline and alpha-tocopherol in the treatment of Alzheimer disease using novel clinical outcomes: Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1996;10:132-40.
70. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M et al. A controlled trial of selegiline, alpha-tocopherol. N Engl J Med 1997;336:1216-22.
71. Saunders AM. Apolipoprotein E and Alzheimer disease: an update on genetic and functional analyses. J Neuropathol Exp Neurol 2000;59:751-8.
72. Saura J, Luque JM, Cesura AM, Da Prada M, Chan-Palay V, Huber G et al. Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography. Neuroscience 1994;62:15-30.
73. Schneider LS, Pollock VE, Zemansky MF, Gleason RP, Palmer R, Sloane RB. A pilot study of low-dose L-deprenyl in Alzheimer's disease. J Geriatr Psychiatr Neurol 1991;4:143-8.
74. Smith RC, Ho BT, Kralik P, Vroulis G, Gordon J, Wolff J. Platelet monamine oxidase in Alzheimer's disease. J Gerontol 1982;37:572-4.
75. Sonsalla PK, Golbe LI. Deprenyl as prophylaxis against Parkinson's disease? Clin Neuropharmacol 1988;11:500-11.
76. Sparks DL, Woeltz VM, Markesbery WR. Alterations in brain monoamine oxidase activity in aging, Alzheimer's disease, and Pick's disease. Arch Neurol 1991;48:718-21.
77. Sramek JJ, Cutler NR. Recent developments in the drug treatment of Alzheimer's disease. Drugs Aging 1999;14:359-73.
78. Steele CD. The genetics of Alzheimer disease. Nurs Clin North Am 2000;35:687-94.
79. Suuronen T, Kolehmainen P, Salminen A. Protective effect of L-deprenyl against apoptosis induced by okadaic acid in cultured neuronal cells. Biochem Pharmacol 2000;59:1589-95.
80. Tang MX, Jacobs D, Stern Y, Marder K, Schofield P, Gurland B et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996;348:429-32.
81. Tanzi RE. Alzheimer's disease risk and the interleukin-1 genes. Ann Neurol 2000;47:283-5.
82. Tariot PN, Cohen RM, Sunderland T, Newhouse PA, Yount D, Mellow AM et al. L-Deprenyl in Alzheimer's disease: preliminary evidence for behavioral change with monoamine oxidase B inhibition. Arch Gen Psychiatr 1987;44:427-33.
83. Thomas T, Rhodin JA, Sutton ET, Bryant MW, Price JM. Estrogen protects peripheral and cerebral blood vessels from toxicity of Alzheimer peptide amyloid-beta and inflammatory reaction. J Submicrosc Cytol Pathol 1999;31:571-9.
84. Thomas T, Bhavnani BR, Thomas P. Inhibition of human LDL oxidation by the neuroprotective drug L-deprenyl. Neurol Res 2002;24:169-73.
85. von Strauss E, Viitanen M, De Ronchi D, Winblad B, Fratiglioni L. Aging and the occurrence of dementia: findings from a population-based cohort with a large sample of nonagenarians. Arch Neurol 1999;56:587-92.
86. Weinstock M, Kirschbaum-Slager N, Lazarovici P, Bejar C, Youdim MB, Shoham S. Neuroprotective effects of novel cholinesterase inhibitors derived from rasagiline as potential anti-Alzheimer drugs. Ann NY Acad Sci 2001;939:148-61.
87. Weyler W, Hsu YP, Breakefield XO. Biochemistry and genetics of monoamine oxidase. Pharmacol Ther 1990;47:391-417.
88. Wilcock GK, Birks J, Whitehead A, Evans SJ. The effect of selegiline in the treatment of people with Alzheimer's disease: a meta-analysis of published trials. Int J Geriatr Psychiatr 2002;17:175-83.
89. Yogev-Falach M, Amit T, Bar-Am O, Weinstock M, Youdim MB. Involvement of MAP kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline. Faseb J 2002;16:1674-6.
90. Yokel RA. The toxicology of aluminum in the brain: a review. Neurotoxicology 2000;21:813-28.
91. Youdim MB, Gross A, Finberg JP. Rasagiline [N-propargyl-1R(+)-aminoindan]. Br J Pharmacol 2001a;132:500-6.
92. Youdim MB, Wadia A, Tatton W, Weinstock M. The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo. Ann NY Acad Sci 2001;939:450-8.
93. Zhou G, Miura Y, Shoji H, Yamada S, Matsuishi T. Platelet monoamine oxidase B and plasma beta-phenylethylamine in Parkinson's disease. J Neurol Neurosurg Psychiatr 2001;70:229-31.